New York Institute of Technology School of Management

Precision BioSciences Announces Senior Leadership Organizational Changes

Retrieved on: 
Friday, September 2, 2022
Health, Genetics, General Health, Research, Science, Biotechnology, AbbVie, Novartis, University, CEO, Technology, Safety, Research, CAR, Gene editing, BS, Time, Johns Hopkins School of Medicine, Protein, New York Institute of Technology School of Management, Achievement, Impax, Infection, Board, Business development, Molecular biology, Johns Hopkins, Forward-looking statement, Chief business officer, SEC, Duke University, Biochemistry, Pennsylvania State University, Lilly, Genome, Precision, MBA, Protein engineering, Leadership, List, Nasdaq, Publication, Biotechnology, Board of directors, Project, University of California, San Francisco, SEC filing, Investor, Director, Industry, Private Securities Litigation Reform Act, Halozyme, Patient, Management, Pharmaceutical industry, Vaccine, Alliance

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the companys senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO).

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities within the companys senior leadership team reporting to Michael Amoroso, Chief Executive Officer (CEO).
  • With these new organizational changes at this time in our company life cycle, Precision BioSciences is poised to continue taking important steps toward becoming a commercial stage company to improve the lives of patients in need.
  • Im very excited about the next chapter for Precision BioSciences and enthusiastic about my new role, said Dr. Jantz.
  • Dr. Jantz has led the development of Precisions allogeneic CAR T and in vivo editing platforms since co-founding Precision BioSciences.

Fusion Fuel Announces Senior Hires as Company Strengthens Core Capabilities, Prepares to Expand Geographic Footprint

Retrieved on: 
Friday, October 15, 2021
Hydrogen, People, Strategic planning, PEM, Air Products & Chemicals, Head, Human resources, Hospitality, EMEA, Industry, Private Securities Litigation Reform Act, Senior, ACA, Executive Committee, Security (finance), Economics, Rise Asset Development, National Physical Laboratory, National College, National College of Ireland, National Physical Laboratory (United Kingdom), KPMG, Michelin, Development, GLOBE, New York Institute of Technology School of Management, U.S. Securities and Exchange Commission, R, Forward-looking statement, S-1 Executive Committee, Company, New Zealand Institute of Chartered Accountants, Natural gas, Annual report, Institute, Sale, NASDAQ, Process engineering, Human, Audit, Lithium

Frederico Figueira de Chaves, Fusion Fuels Chief Financial Officer, offered his thoughts on the new hires: We are excited to welcome these immensely talented individuals to the Fusion Fuel team.

Key Points: 
  • Frederico Figueira de Chaves, Fusion Fuels Chief Financial Officer, offered his thoughts on the new hires: We are excited to welcome these immensely talented individuals to the Fusion Fuel team.
  • This is a critical time for the Company as we begin to ramp up our commercial operations across the globe.
  • Lus Castanheira, Senior R&D Engineer Lus will lead Fusion Fuels R&D efforts in the electrochemical and membrane space.
  • Any forward-looking statement made by Fusion Fuel herein speaks only as of the date on which it is made.